Format
Sort by
Items per page

Send to

Choose Destination

Best matches for López-Cortés LF[au]:

Impact of HIV on the severity of influenza. González Álvarez DA et al. Expert Rev Respir Med. (2016)

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients. Gutierrez-Valencia A et al. J Antimicrob Chemother. (2017)

Antiretroviral Therapy in Early HIV Infection. Lopez-Cortes LF et al. N Engl J Med. (2016)

Search results

Items: 1 to 50 of 130

1.

Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions.

Neukam K, Gutiérrez-Valencia A, Llaves-Flores S, Espinosa N, Viciana P, López-Cortés LF.

Vaccine. 2019 May 6;37(20):2758-2763. doi: 10.1016/j.vaccine.2019.03.029. Epub 2019 Apr 10.

PMID:
30981625
2.

Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice.

Neukam K, Delgado Fernández M, Hernández Quero J, Rivero-Juárez A, Llaves-Flores S, Jiménez Oñate F, Gutiérrez-Valencia A, Espinosa N, Viciana P, López-Cortés LF.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):e1-e5. doi: 10.1097/QAI.0000000000001990.

PMID:
30865187
3.

High-risk human papilloma virus testing improves diagnostic performance to predict moderate-to-high grade anal intraepithelial neoplasia in HIV-infected men who have sex with men in low-to-absent cytological abnormalities.

Viciana P, Milanés-Guisado Y, Fontillón M, Castaño AD, Sotomayor C, Espinosa N, López-Cortés LF, Neukam K; SeVIHanal Study Group.

Clin Infect Dis. 2019 Feb 16. pii: ciz144. doi: 10.1093/cid/ciz144. [Epub ahead of print]

PMID:
30770528
4.

High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance.

Neukam K, Milanés Guisado Y, Fontillón M, Merino L, Sotomayor C, Espinosa N, López-Cortés LF, Viciana P; SeVIHanal Study Group.

Papillomavirus Res. 2019 Jun;7:62-66. doi: 10.1016/j.pvr.2019.01.003. Epub 2019 Feb 1.

5.

Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment.

Milanés-Guisado Y, Gutiérrez-Valencia A, Trujillo-Rodríguez M, Espinosa N, Viciana P, López-Cortés LF.

PLoS One. 2018 Oct 22;13(10):e0205777. doi: 10.1371/journal.pone.0205777. eCollection 2018.

6.

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.

Gutierrez-Valencia A, García C, Viciana P, Milanés-Guisado Y, Fernandez-Magdaleno T, Espinosa N, Pasquau J, López-Cortés LF.

PLoS One. 2018 Sep 20;13(9):e0203452. doi: 10.1371/journal.pone.0203452. eCollection 2018.

7.

Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.

López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, Benmarzouk-Hidalgo OJ, Dominguez-Molina B, Milanés-Guisado Y, Espinosa N, Viciana P, Gutiérrez-Valencia A.

J Infect Dis. 2018 Jul 13;218(4):624-632. doi: 10.1093/infdis/jiy136.

PMID:
29986086
8.

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.

Gutierrez-Valencia A, Trujillo-Rodriguez M, Fernandez-Magdaleno T, Espinosa N, Viciana P, López-Cortés LF.

J Int AIDS Soc. 2018 Feb;21(2). doi: 10.1002/jia2.25072.

9.

Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial.

Gutierrez-Valencia A, Benmarzouk-Hidalgo OJ, Rivas-Jeremías I, Espinosa N, Trujillo-Rodríguez M, Fernandez-Magdaleno T, Viciana P, López-Cortés LF.

Clin Infect Dis. 2017 Aug 15;65(4):551-556. doi: 10.1093/cid/cix358.

PMID:
28449051
10.

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.

Gutierrez-Valencia A, Benmarzouk-Hidalgo OJ, Llaves S, Fernandez-Magdaleno T, Espinosa N, Viciana P, Lopez-Cortes LF.

J Antimicrob Chemother. 2017 Mar 1;72(3):816-819. doi: 10.1093/jac/dkw487.

PMID:
27999051
11.

Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.

Rivero-Juarez A, Lopez-Cortes LF, Castaño M, Merino D, Marquez M, Mancebo M, Cuenca-Lopez F, Jimenez-Aguilar P, Lopez-Montesinos I, Lopez-Cardenas S, Collado A, Lopez-Ruz MA, Omar M, Tellez F, Perez-Stachowski X, Hernandez-Quero J, Girón-Gonzalez JA, Fernandez-Fuertes E, Rivero A; HERACLES cohort study team of the Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):487-494. doi: 10.1007/s10096-016-2822-6. Epub 2016 Oct 27.

12.

Early initiation of antiretroviral therapy: debate over?

Lopez-Cortes LF, Gutierrez-Valencia A, Ben-Marzouk-Hidalgo OJ.

Lancet Infect Dis. 2016 Jul;16(7):769. doi: 10.1016/S1473-3099(16)30077-9. No abstract available.

PMID:
27352744
13.

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.

Falcon-Neyra L, Palladino C, Navarro Gómez ML, Soler-Palacín P, González-Tomé MI, De Ory SJ, Frick MA, Fortuny C, Noguera-Julian A, Moreno EB, Santos JL, Olbrich P, López-Cortés LF, Briz V, Neth O; CoRISpe working group.

Medicine (Baltimore). 2016 Jun;95(24):e3842. doi: 10.1097/MD.0000000000003842. Erratum in: Medicine (Baltimore). 2016 Aug 07;95(31):e5074.

14.

Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

Parra Millán R, Jiménez Mejías ME, Sánchez Encinales V, Ayerbe Algaba R, Gutiérrez Valencia A, Pachón Ibáñez ME, Díaz C, Pérez Del Palacio J, López Cortés LF, Pachón J, Smani Y.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4464-70. doi: 10.1128/AAC.02708-15. Print 2016 Aug.

15.

HIV-1 p24 and CD4+ T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients.

Benmarzouk-Hidalgo OJ, Torres-Cornejo A, Gutierrez-Valencia A, Viciana P, López-Cortés LF.

Enferm Infecc Microbiol Clin. 2017 Mar;35(3):174-178. doi: 10.1016/j.eimc.2016.02.001. Epub 2016 Mar 11. English, Spanish.

PMID:
26976380
16.

Impact of HIV on the severity of influenza.

González Álvarez DA, López Cortés LF, Cordero E.

Expert Rev Respir Med. 2016 Apr;10(4):463-472. doi: 10.1586/17476348.2016.1157474. Epub 2016 Mar 10.

PMID:
26918376
17.

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.

López-Cortés LF, Castaño MA, López-Ruz MA, Rios-Villegas MJ, Hernández-Quero J, Merino D, Jiménez-Aguilar P, Marquez-Solero M, Terrón-Pernía A, Tellez-Pérez F, Viciana P, Orihuela-Cañadas F, Palacios-Baena Z, Vinuesa-Garcia D, Fajardo-Pico JM, Romero-Palacios A, Ojeda-Burgos G, Pasquau-Liaño J.

PLoS One. 2016 Feb 12;11(2):e0148924. doi: 10.1371/journal.pone.0148924. eCollection 2016.

18.

Antiretroviral Therapy in Early HIV Infection.

Lopez-Cortes LF, Gutiérrez-Valencia A, Ben-Marzouk-Hidalgo OJ.

N Engl J Med. 2016 Jan 28;374(4):393. doi: 10.1056/NEJMc1513311. No abstract available.

PMID:
26816020
19.

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.

Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA.

PLoS One. 2015 Dec 7;10(12):e0143492. doi: 10.1371/journal.pone.0143492. eCollection 2015.

20.

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?

Gutierrez-Valencia A, Chacón-Mora N, Ruiz-Valderas R, Ben-Marzouk-Hidalgo OJ, Torres-Cornejo A, Viciana P, Lopez-Cortes LF.

Medicine (Baltimore). 2015 Oct;94(43):e1743. doi: 10.1097/MD.0000000000001743.

21.

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract.

Torres-Cornejo A, BenMarzouk-Hidalgo OJ, Viciana P, Sánchez B, López-Ruz MA, López-Cortés LF, Gutiérrez-Valencia A.

Clin Microbiol Infect. 2016 Jan;22(1):98.e7-98.e10. doi: 10.1016/j.cmi.2015.09.028. Epub 2015 Oct 8.

22.

Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.

BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutierrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):6-11. doi: 10.1089/AID.2014.0299. Epub 2015 Oct 21.

PMID:
26414169
23.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain.

Rivero-Juarez A, Gutierrez-Valencia A, Castaño M, Merino D, Neukam K, Ríos-Villegas MJ, Lopez-Ruz MA, Jiménez-Aguilar P, Marquez M, Collado A, Gomez-Vidal A, Hernandez-Quero J, Tellez F, Fernandez-Fuertes E, Rivero A, López-Cortés LF; Group for the Study of Viral Hepatitis (HEPAVIR) of the Andalusian Society of Infectious Diseases (SAEI).

Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2247-55. doi: 10.1007/s10096-015-2476-9. Epub 2015 Sep 5.

24.

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.

Mira JA, Neukam K, López-Cortés LF, Rivero-Juárez A, Téllez F, Girón-González JA, de los Santos-Gil I, Ojeda-Burgos G, Merino D, Ríos-Villegas MJ, Collado A, Torres-Cornejo A, Macías J, Rivero A, Pérez-Pérez M, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI); Red de Investigación en SIDA (RIS-HEP07).

Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1879-84. doi: 10.1007/s10096-015-2426-6. Epub 2015 Jun 27.

PMID:
26115631
25.

Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.

BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

Medicine (Baltimore). 2015 May;94(17):e781. doi: 10.1097/MD.0000000000000781.

26.

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.

Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, Bhagani S, López-Cortés LF, Haberl A, Stoeckle M, Márquez M, Scholten S, de Los Santos-Gil I, Mauss S, Rivero A, Collado A, Delgado M, Rockstroh JK, Pineda JA.

PLoS One. 2015 Apr 29;10(4):e0125080. doi: 10.1371/journal.pone.0125080. eCollection 2015.

27.

Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.

Gutierrez-Valencia A, Ruiz-Valderas R, Ben-Marzouk-Hidalgo OJ, Torres-Cornejo A, Espinosa N, Castillo-Ferrando JR, Viciana P, Lopez-Cortes LF.

Antimicrob Agents Chemother. 2015;59(6):3257-62. doi: 10.1128/AAC.04795-14. Epub 2015 Mar 23.

28.

Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.

Macías J, Mancebo M, Márquez M, Merino D, Téllez F, Rivero A, von Wichmann MA, López-Cortés LF, Merchante N, Santos J, Raffo M, Pérez-Pérez M, Camacho Á, Iribarren JA, Pineda JA.

Hepatology. 2015 May;61(5):1503-11. doi: 10.1002/hep.27674. Epub 2015 Mar 20.

PMID:
25545020
29.

Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.

Corchado S, López-Cortés LF, Rivero-Juárez A, Torres-Cornejo A, Rivero A, Márquez-Coello M, Girón-González JA.

PLoS One. 2014 Jul 11;9(7):e101760. doi: 10.1371/journal.pone.0101760. eCollection 2014.

30.

HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.

Rivero-Juarez A, López-Cortés LF, Camacho A, Torres-Cornejo A, Gordon A, Ruiz-Valderas R, Torre-Cisneros J, Pineda JA, Viciana P, Rivero A.

PLoS One. 2014 Jun 19;9(6):e99468. doi: 10.1371/journal.pone.0099468. eCollection 2014.

31.

Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.

Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Gutierrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

HIV Med. 2015 Jan;16(1):57-61. doi: 10.1111/hiv.12170. Epub 2014 Jun 9.

32.

Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population.

López-Cortés LF, Viciana P, Girón-González JA, Romero-Palacios A, Márquez-Solero M, Martinez-Perez MA, López-Ruz MA, de la Torre-Lima J, Téllez-Pérez F, Delgado-Fernández M, Garcia-Lázaro M, Lozano F, Mohamed-Balghata MO; Sociedad Andaluza de Enfermedades Infecciosas.

PLoS One. 2014 May 16;9(5):e97262. doi: 10.1371/journal.pone.0097262. eCollection 2014.

33.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.

Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.

J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17.

PMID:
24438679
34.

Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.

Gutierrez-Valencia A, Torres-Cornejo A, BenMarzouk-Hidalgo OJ, Ruiz-Valderas R, Lluch A, Viciana P, López-Cortés LF.

Antivir Ther. 2014;19(5):443-7. doi: 10.3851/IMP2722. Epub 2014 Jan 16.

PMID:
24434370
35.

Immune activation throughout a boosted darunavir monotherapy simplification strategy.

BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF.

Clin Microbiol Infect. 2014 Dec;20(12):1297-303. doi: 10.1111/1469-0691.12521. Epub 2014 Feb 10.

36.

Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.

Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Gutiérrez-Valencia A, Pérez-Romero P, Martín-Peña R, Ruiz-Valderas R, Viciana P, Lopez-Cortes LF.

AIDS. 2014 Jan 14;28(2):201-8. doi: 10.1097/QAD.0000000000000060.

PMID:
24361681
37.

Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.

Rivero-Juarez A, Lopez-Cortes LF, Girón-Gonzalez JA, Pineda JA, Rivero A; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas.

Lancet Infect Dis. 2014 Jan;14(1):13-14. doi: 10.1016/S1473-3099(13)70359-1. No abstract available.

PMID:
24355031
38.

[Safety profile of rilpivirine: general and neuropsychiatric tolerability, safety in patients with hepatitis B or C viruses, and lipid profile].

López Cortés LF, Martínez E, von Wichmann MÁ.

Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:6-11. doi: 10.1016/S0213-005X(13)70137-X. Review. Spanish.

PMID:
24252528
39.

Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.

Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF.

Clin Infect Dis. 2014 Jan;58(2):268-73. doi: 10.1093/cid/cit693. Epub 2013 Oct 21.

PMID:
24145880
40.

A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.

Rivero-Juarez A, López-Cortés LF, Camacho A, Mira JA, Téllez F, Marquez M, Merino D, Pineda JA, Rivero A; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR), part of the Sociedad Andaluza de Enfermedades Infecciosas.

Clin Infect Dis. 2014 Jan;58(1):130-3. doi: 10.1093/cid/cit653. Epub 2013 Sep 24.

PMID:
24065317
41.

Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.

Macías J, Márquez M, Téllez F, Merino D, Jiménez-Aguilar P, López-Cortés LF, Ortega E, von Wichmann MA, Rivero A, Mancebo M, Santos J, Pérez-Pérez M, Suárez-Lozano I, Romero-Palacios A, Torres-Cornejo A, Pineda JA.

Clin Infect Dis. 2013 Nov;57(10):1401-8. doi: 10.1093/cid/cit537. Epub 2013 Aug 14.

PMID:
23946224
42.

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.

Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martinez-Dueñas L, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.

AIDS. 2013 Jul 31;27(12):1941-7. doi: 10.1097/QAD.0b013e328360ea1e.

PMID:
23917425
43.

Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.

Macías J, Camacho A, Von Wichmann MA, López-Cortés LF, Ortega E, Tural C, Ríos MJ, Merino D, Téllez F, Márquez M, Mancebo M, Pineda JA.

AIDS. 2013 Oct 23;27(16):2541-9. doi: 10.1097/QAD.0b013e32836381f3.

PMID:
23736148
44.

Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.

Lopez-Cortes LF, Ruiz-Valderas R, Sánchez-Rivas E, Lluch A, Gutierrez-Valencia A, Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Viciana P.

Antimicrob Agents Chemother. 2013 Aug;57(8):3746-51. doi: 10.1128/AAC.00315-13. Epub 2013 May 28.

45.

Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.

Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas.

Clin Infect Dis. 2013 Jun;56(11):1646-53. doi: 10.1093/cid/cit103. Epub 2013 Feb 19.

PMID:
23429381
46.

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.

Rivero-Juárez A, Lopez-Cortes LF, Camacho A, Torres-Cornejo A, Pineda JA, Marquez-Solero M, Caruz A, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.

PLoS One. 2012;7(11):e48959. doi: 10.1371/journal.pone.0048959. Epub 2012 Nov 8.

47.

Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.

Rivero-Juarez A, Mira JA, Santos-Gil I, Lopez-Cortes LF, Girón-Gonzalez JA, Marquez M, Merino D, Tellez F, Caruz A, Pineda JA, Rivero A; Grupo Andaluz Para El Estudio de Las Hepatitis Víricas Hepavir de la Sociedad Andaluza de Enfermedades Infecciosas Saei.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):223-5. doi: 10.1089/AID.2012.0126. Epub 2012 Oct 10.

48.

Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.

Mira JA, García-Rey S, Rivero A, de los Santos-Gil I, López-Cortés LF, Girón-González JA, Téllez F, Márquez M, Merino D, Ríos-Villegas MJ, Macías J, Rivero-Juárez A, Pineda JA.

Clin Infect Dis. 2012 Dec;55(12):1719-26. doi: 10.1093/cid/cis779. Epub 2012 Sep 5.

PMID:
22955435
49.

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.

Mira JA, Rivero A, de Los Santos-Gil I, López-Cortés LF, Girón-González JA, Márquez M, Merino D, del Mar Viloria M, Téllez F, Ríos-Villegas MJ, Omar M, Rivero-Juárez A, Macías J, Pineda JA; Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

AIDS. 2012 Aug 24;26(13):1721-4.

PMID:
22695304
50.

Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases.

Suárez-García I, Jarrín I, Iribarren JA, López-Cortés LF, Lacruz-Rodrigo J, Masiá M, Gómez-Sirvent JL, Hernández-Quero J, Vidal F, Alejos-Ferreras B, Moreno S, Del Amo J.

Enferm Infecc Microbiol Clin. 2013 May;31(5):304-12. doi: 10.1016/j.eimc.2012.03.009. Epub 2012 May 18.

PMID:
22608566

Supplemental Content

Loading ...
Support Center